SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-041171
Filing Date
2023-11-14
Accepted
2023-11-14 16:30:38
Documents
46
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 929092
2 ex10-3.htm EX-10.3 142578
3 ex31-1.htm EX-31.1 9089
4 ex31-2.htm EX-31.2 8968
5 ex32-1.htm EX-32.1 5466
  Complete submission text file 0001493152-23-041171.txt   3036226

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE aneb-20230930.xsd EX-101.SCH 20303
7 XBRL CALCULATION FILE aneb-20230930_cal.xml EX-101.CAL 26901
8 XBRL DEFINITION FILE aneb-20230930_def.xml EX-101.DEF 61312
9 XBRL LABEL FILE aneb-20230930_lab.xml EX-101.LAB 178254
10 XBRL PRESENTATION FILE aneb-20230930_pre.xml EX-101.PRE 137509
40 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 208721
Mailing Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734
Business Address JFL CAPITAL MANAGEMENT 1017 RR 620 S, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

IRS No.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-40388 | Film No.: 231406982
SIC: 2834 Pharmaceutical Preparations